Covid-19 in Hematological Malignancies (EPICOVIDEHA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04733729|
Recruitment Status : Recruiting
First Posted : February 2, 2021
Last Update Posted : October 26, 2022
|Condition or disease|
|COVID-19 Infection in Hematological Malignancies Patients|
At the moment, few data on the epidemiology of SARS-CoV-2 infection in patients suffering from hematological malignancies are available. However, the COVID-19 pandemic presents unique challenges and opportunities on hematological malignancies. The future trajectory of this pandemic appears to be growing and hematology communities must continue to prepare for its spread In this project, we will implement cooperation between all members of the hematology departments both within the EHA and outside it, in order to evaluate the epidemiological data on the incidence and outcome in patients with hematological malignancies infected with SARS-CoV-2.
We will provide useful information to inform the individualized plan for patients with hematological malignancies.
We aim to evaluate the epidemiology and outcomes of patients with HM infected with COVID-19,estimate the incidence and type of disease, assess the acute and long-term mortality rate and estimate the overall mortality rate of cases.
This is a cohort retrospective/prospective survey. In the retrospective phase of the study, participating centers will retrospectively review episodes of COVID-19 disease that occurred in patients with hematological malignancies identified at their institutions from February 2020 to December 2020. In the prospective phase of the study, the researchers will include episodes of COVID-19 disease from the start of the study through December 31, 2021.
The study population will need to be over 18 with hematological malignancies and SARS-CoV-2 An electronic database with anonymization will be created and available to collect all information with single access for each participating institution. The data collected will be demographic data,epidemiological factors, admission information, COVID-19 disease severity, history of hematological malignancies, disease status with past / current treatments, and 30 days of diagnosis.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||3000 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey|
|Actual Study Start Date :||March 1, 2020|
|Actual Primary Completion Date :||September 30, 2022|
|Estimated Study Completion Date :||March 31, 2024|
- Epidemiology of COVID-19 infection in patients with hematological malignancies [ Time Frame: 2020 (1 year) ]to evaluate the epidemiology of COVID infection among all hema malignancies patients subgroups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04733729
|Contact: livio pagano, Proffirstname.lastname@example.org|
|Contact: Jon Salmanton Garcia, Dremail@example.com|
|Contact: Chiara Cattaneo|
|AOU Policlinico Federico II||Recruiting|
|Contact: Marco Picardi|
|Fondazione Policlinico A. Gemelli IRCCS||Recruiting|
|Contact: Livio Pagano|
|Contact: Marianna Criscuolo|
|Istituto Nazionale Tumori Regina Elena IFO||Recruiting|
|Contact: Francesco Marchesi|
|Osp. di Circolo-Fondazione Macchi||Recruiting|
|Contact: Claudia Maria Basilico|
|Contact: Gianpaolo Nadali|